Form D · Pharmaceuticals
TYME TECHNOLOGIES, INC.
New York, NY · CIK 0001537917
Offering snapshot reported Jan 21, 2020 · SEC filing
- Reported sold
- $20M Offering amount: $20M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $20M Reported outside-investor minimum
- First sale
- Jan 7, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 21, 2020 | Initial | $20,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-358592
Source: Form D, filed Jan 21, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Carberry | Director |
| Donald De Golyer | Director |
| Giuseppe Del Priore | Executive |
| Jonathan Eckard | Executive |
| Barbara Galani | Executive |
| Steve Hoffman | Director, Executive |
| Michele Korfin | Executive |
| Douglas Michels | Director |
| Gerald H. Sokol | Director |
| Paul Sturman | Director |
| Ben R. Taylor | Executive |
| Tommy G. Thompson | Director |
| Timothy C. Tyson | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
17 State Street 7 Th Floor
New York, NY, 10004
New York, NY, 10004